Abstract
The presence of Fusobacterium nucleatum (F. nucleatum) in the community of colorectal cancer (CRC) accounts for its chemotherapy resistance. To resolve this drawback, we prepared multifaceted supramolecular nanomedicine by conjugating lauric acid (LA) and platinum (IV) oxaliplatin prodrug to hyperbranched polyglycidyl ether (PG), followed by addition of cucurbit[7]uril (CB[7]) to elicit supramolecular assembly. In principle, LA is used to eliminate the F. nucleatum, thereby enhancing chemotherapeutic efficacy of oxaliplatin. CB[7] facilitates host–guest complexation with oxaliplatin, allowing its activation specifically in the spermine-overexpressed CRC tumors. Moreover, CB[7] conduces to supramolecular assembly between the self-assembly units of PG-Pt-LA nanoparticles, representing a novel size-transformable supramolecular nanomedicine (PG-Pt-LA/CB[7]), which can address the dilemma of long circulation and deep penetration existed in nanomedicine. In F. nucleatum co-localized HT29 mouse model and CT26luc mouse model, PG-Pt-LA/CB[7] is validated to be a targeted, safe and effective nanomedicine that can substantially promote the chemotherapeutic efficacy in the treatment of drug-resistant CRC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
